Skip to content

Find a Doctor

With more than 1900 primary care physicians and specialists, NorthShore University HealthSystem offers a team of experts representing a vast array of specialties, you have a choice of leading medical experts for you to select from for your care.

Marshall S. Baker, M.D.

Conditions & Procedures

Conditions

Abscess, Appendix, Cyst, Gallbladder, Gallbladder Disease, Hernia, Lipoma, Liver, Liver Cancer, Melanoma, Pancreaticobiliary Disease, Sarcoma, Skin Lesion

Procedures

Bile Duct Surgery, Biliary Surgery, Colon, Colon/Rectal Surgery, General Surgery, Hepatobiliary and Oncologic Surgery, Hepatobiliary Surgery, Liver and Biliary Oncologic Surgery, Liver Surgery, Minimally Invasive Hernia Surgery, Minimally Invasive Stomach, Oncologic Surgery, Pancreas Surgery and Management, Pancreatic Cancer and Disease Management, Pancreatic Surgery, Peritoneal Dialysis (PD) Catheter, Port-a-cath, Surgical Oncology, Temporal Artery Biopsy
General Information

Gender

Male

Affiliation

NorthShore Medical Group

Expertise

General Surgery, Oncologic Surgery, Pancreatic Cancer

Academic Rank

Clinical Assistant Professor

Languages

English

Board Certified

Surgery

Clinical Service

Surgical Oncology
Education, Training & Fellowships

Medical School

Dartmouth Medical School, 1998

Internship

Georgetown University Hospital, 2000

Residency

Northwestern Feinberg School of Medicine, 2006

Fellowship

Northwestern Feinberg School of Medicine, 2003 Indiana University School of Medicine, 2007
A

NorthShore Medical Group

1000 Central St.
Suite 800
Evanston, IL 60201
847.570.1700 847.570.1330 fax This location is wheelchair accessible.
B

NorthShore Medical Group

2050 Pfingsten Rd
Suite 128
Glenview, IL 60026
847.570.1700 847.570.1330 fax This location is wheelchair accessible.
C

NorthShore Medical Group

225 N. Milwaukee Ave.
Suite 1500
Vernon Hills, IL 60061
847.570.1700 847.570.1330 fax This location is wheelchair accessible.
D

NorthShore Medical Group

2650 Ridge Ave.
Kellogg Cancer Center
Evanston, IL 60201
847.570.1700 847.570.1330 fax This location is wheelchair accessible.

Every effort has been made to ensure the accuracy of the information in this directory. However, some changes may occur between updates. Please check with your provider to ensure that he or she participates in your health plan.

Aetna HMO/PPO/POS
BCBS HMOI
BCBS POS-- Blue Choice
BCBS PPO - BCBS PPO
Beechstreet PPO
CCN PPO
CIGNA Choice Fund
CIGNA Choice Fund PPO
CIGNA EPO
CIGNA Network
CIGNA Network Open Access
CIGNA POS
CIGNA POS Open Access
CIGNA PPO
CIGNA:Open Access Plus
First Health PPO
Galaxy PPO
Great West POS
Great West PPO
Healthcares Finest Network PPO
Humana Choice Care PPO
Humana IPA--HMO
Humana POS
Humana PPO
Medicare Cook County
Medicare Lake County
Multiplan Admar PPO
Multiplan Formost PPO
Multiplan Health Network PPO
Multiplan Wellmark PPO
NorthShore Employee Network
PHCS PPO
Preferred Plan PPO
Railroad Medicare - Cook County
UHC All Commercial Products
Unicare PPO
  • CA 19-9 Nonproduction Is Associated With Poor Survival After Resection of Pancreatic Adenocarcinoma.

    Am J Clin Oncol. 2013 Feb 20;

    Authors: Hayman AV, Stocker SJ, Baker MS, Bentrem DJ, Prinz RA, Marsh RD, Talamonti MS

    Abstract
    BACKGROUND:: Carbohydrate antigen (CA) 19-9 is the most common serum biomarker used in pancreatic adenocarcinoma (PC). Elevated preoperative levels have been shown to correlate with more advanced stage, greater risk of unresectability, and overall worse survival. The prognostic value of CA 19-9 nonproduction, which is present in an estimated 5% to 15% of the population, is unclear. We sought to determine whether CA 19-9 nonproduction was associated with worse survival after PC resection. METHODS:: We retrospectively reviewed our institution's prospective pancreatic database for all PC patients with documented preoperative CA 19-9 values who underwent resection with curative intent from March 1992 to August 2009. After excluding 10 perioperative deaths, 200 patients remained for analysis. RESULTS:: Mean and median follow-up was 23.3 and 16.1 months, respectively. Median survival in months for patients with preoperative CA 19-9 levels in U/mL by category was as follows: normal (5.1 to 36.9): 32, nonproduction (≤5): 21, mildly elevated (37 to 99.9): 35, highly elevated (100+): 16. Factors significantly associated with worse overall survival were: nonwhite race, nonproduction or highly elevated preoperative CA 19-9 (≥100 U/mL), estimated blood loss ≥1 L, tumor size (≥2 cm), lymph node-positivity, and advanced (3/4) histologic grade. On multivariate analysis, only CA 19-9 nonproduction or highly elevated production, estimated blood loss ≥1 L, advanced histologic grade, and node positivity remained significant in the final model. CONCLUSIONS:: CA 19-9 nonproduction is not associated with improved survival after pancreatic cancer resection, as has previously been asserted, when compared with patients with normal and elevated levels.

    PMID: 23428954 [PubMed - as supplied by publisher]

Showing results 1 - 1 of 1
Page size:
1